Karin Bosshard Livres

Focusing on the legal and economic implications of the EU's Alternative Investment Fund Manager Directive (AIFMD), this book explores its effects on Swiss hedge funds. It analyzes how Swiss policymakers can effectively adapt to the new EU regulations. The legal analysis is grounded in relevant legislative texts and expert opinions, while the economic evaluation assesses various strategic responses available to hedge fund managers and advisors, bolstered by insights from industry professionals.

The book adds to the discussion about strategic approaches towards the translation of personalized medicine into clinical practice. It stresses the importance of non-science related, institutional barriers. A Law and Economics perspective is applied in order to examine the incentives induced by the barriers. An applied part identifies and evaluates policy levers to foster the translation of personalized medicine into Swiss clinical practice.